Seventure

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs
9 September 2021

ViroVet and The Pirbright Institute are first to demonstrate efficacy of antivirals in ASFV – African Swine Fever Virus – infected pigs

Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine...

Read the press release
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
16 June 2021

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting...

Read the press release
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
24 March 2021

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical...

Read the press release
Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG
18 March 2021

Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners explains Why investors need to think beyond ESG

Calls for genuine corporate responsibility efforts have been high on the agenda for some time, but the pandemic — and its wide-ranging impact on all organisations, including...

Read more
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
17 March 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...

Read the press release
YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders,  as well as the Inclusion of the Obese Patients in the Second Arm of the Trial
4 March 2021

YSOPIA Bioscience Announces the First Positive Safety Results of its CAUSALITY Study in Obesity and Associated Metabolic Disorders, as well as the Inclusion of the Obese Patients in the Second Arm of the Trial

YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative drugs using the properties of key bacterial strains...

Read the press release
BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin
2 March 2021

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that...

Read the press release
Izicap awarded “Best Pos/payment solution 2021” MPE AWARDS
25 February 2021

Izicap awarded “Best Pos/payment solution 2021” MPE AWARDS

Izicap, the european card-linked CRM & loyalty platform leader, has been awarded "Best POS/Payment Solution" by the merchant payments ecosystem organisation within their...

Read more
Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments
9 February 2021

Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments

Seventure led $10M round for new French company focusing on I/O-microbiome and provided $3M seed funding to ErVaccine, driving an increased I/O microbiome focus in fund...

Read the press release
Proteon Pharmaceuticals and Skretting to co-develop new phage-based solutions for aquaculture
27 January 2021

Proteon Pharmaceuticals and Skretting to co-develop new phage-based solutions for aquaculture

Proteon Pharmaceuticals announced a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry. The...

Read more